Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

被引:240
作者
Jose Lahuerta, Juan
Victoria Mateos, Maria
Martinez-Lopez, Joaquin
Rosinol, Laura
Sureda, Anna
de la Rubia, Javier
Garcia-Larana, Jose
Martinez-Martinez, Rafael
Hernandez-Garcia, Miguel T.
Carrera, Dolores
Besalduch, Joan
de Arriba, Felipe
Maria Ribera, Jose
Escoda, Lourdes
Hernandez-Ruiz, Belen
Garcia-Frade, Javier
Rivas-Gonzalez, Concepcion
Alegre, Adrian
Blade, Joan
San Miguel, Jesus F.
机构
[1] Univ Salemanca, Hosp Univ Salamanca, Ctr Invest Canc,Ctr Super Invest Aentif Salamanca, Inst Biol Mol & Celular Canc Salamanca, Barcelona, Spain
[2] Hosp Univ 12 Octubre, Madrid, Spain
[3] Hosp Univ Ramon & Cajal, Madrid, Spain
[4] Hosp Univ Princesa, Madrid, Spain
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[7] Hosp La Fe, E-46009 Valencia, Spain
[8] Hosp Univ Canarias, Canarias, Spain
[9] Hosp Cent Asturias, Asturias, Spain
[10] Complejo Asistencial Son Dureta, Palma de Mallorca, Spain
[11] Hosp Gen Morales Messeguer, Murcia, Spain
[12] Hosp Gemans Trias & Pujol, Badalona, Spain
[13] Hosp Joan 23, Tarragona, Spain
[14] Hosp Nuestra Senora Alarcos, Ciudad Real, Spain
[15] Hosp Rio Ortega, Valladolid, Spain
[16] Hosp Gen Univ, Alicante, Spain
关键词
D O I
10.1200/JCO.2008.17.9721
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial response (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM. Patients and Methods We analyzed 632 patients from the prospective Grupo Espanol de Mieloma 2000 protocol who were uniformly treated with vincristine, carmustine, cyclophosphamide, melphalan, and predisone/vincristine, carmustine, adryamcine, and dexamethasone induction followed by high-dose therapy and autologous stem-cell transplantation. Results Post-transplantation response markedly influenced outcomes. Patients achieving CR had significantly longer EFS (median, 61 v 40 months; P < 10(-5)) and OS (medians not reached; P = .01) versus patients achieving nCR, who likewise had somewhat better outcomes compared with patients achieving PR (median EFS, 34 months, P = .07 v nCR; median OS, 61 months, P = .04). EFS and OS and influence of response were similar among older (age 65 to 70 years) and younger (age < 65 years) patients. Similar findings were observed with pretransplantation response, with trends toward EFS (P =. 1; P =. 05) and OS (P = .1; P = .07) benefit in patients achieving CR versus nCR and PR, respectively. Post-transplantation response was markedly influenced by pretransplantation response; improvements in response were associated with prolonged survival. Conclusion Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM. There were trends toward similar associations with pretransplantation response status.
引用
收藏
页码:5775 / 5782
页数:8
相关论文
共 49 条
[1]   Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma [J].
Alexanian, R ;
Weber, D ;
Giralt, S ;
Dimopoulos, M ;
Delasalle, K ;
Smith, T ;
Champlin, R .
BONE MARROW TRANSPLANTATION, 2001, 27 (10) :1037-1043
[2]   Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments [J].
Alvares, CL ;
Davies, FE ;
Horton, CS ;
Patel, G ;
Powles, R ;
Sirohi, B ;
Zuha, R ;
Gatt, A ;
Saso, R ;
Treleaven, JG ;
Dearden, CE ;
Potter, MN ;
Ethell, ME ;
Morgan, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (05) :607-614
[3]  
[Anonymous], 1998, J Clin Oncol, V16, P3832
[4]   Single versus double autologous stem-cell transplantation for multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Facon, T ;
Guilhot, F ;
Doyen, C ;
Fuzibet, JG ;
Monconduit, M ;
Hulin, C ;
Caillot, D ;
Bouabdallah, R ;
Voillat, L ;
Sotto, JJ ;
Grosbois, B ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502
[5]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[6]  
BARBUI AM, 2001, BLOOD, V683, pA210
[7]  
BARLOGIE B, 1986, BLOOD, V67, P1298
[8]   Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].
Barlogie, B ;
Tricot, G ;
Anaissie, E ;
Shaughnessy, J ;
Rasmussen, E ;
van Rhee, F ;
Fassas, A ;
Zangari, M ;
Hollmig, K ;
Pineda-Roman, M ;
Lee, C ;
Talamo, G ;
Thertulien, R ;
Kiwan, E ;
Krishna, S ;
Fox, M ;
Crowley, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030
[9]   PROGNOSTIC FACTORS IN AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR MULTIPLE-MYELOMA - AN EBMT REGISTRY STUDY [J].
BJORKSTRAND, B ;
GOLDSTONE, AH ;
LJUNGMAN, P ;
BRANDT, L ;
BRUNET, S ;
CARLSON, K ;
PRENTICE, HG ;
CAVO, M ;
SAMSON, D ;
DELAURENZI, A ;
VERDONCK, LF ;
PROCTOR, S ;
FERRANT, A ;
SIERRA, J ;
AUZANNEAU, G ;
TROUSSARD, X ;
GRAVETT, P ;
REMES, K ;
GAHRTON, G .
LEUKEMIA & LYMPHOMA, 1994, 15 (3-4) :265-272
[10]   Transplantation for multiple myeloma:: who, when, how often?: High-dose therapy in multiple myeloma [J].
Bladé, J .
BLOOD, 2003, 102 (10) :3469-3470